GSA Capital Partners LLP Makes New $152,000 Investment in Sutro Biopharma, Inc. $STRO

GSA Capital Partners LLP purchased a new stake in Sutro Biopharma, Inc. (NASDAQ:STRO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 174,843 shares of the company’s stock, valued at approximately $152,000.

Several other hedge funds and other institutional investors have also made changes to their positions in STRO. Catalyst Funds Management Pty Ltd bought a new position in Sutro Biopharma in the 2nd quarter worth approximately $27,000. Savant Capital LLC acquired a new position in Sutro Biopharma during the 2nd quarter worth $37,000. CWM LLC grew its stake in shares of Sutro Biopharma by 73.2% in the second quarter. CWM LLC now owns 56,657 shares of the company’s stock worth $40,000 after purchasing an additional 23,941 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Sutro Biopharma during the second quarter valued at $48,000. Finally, Invesco Ltd. raised its stake in shares of Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after purchasing an additional 53,390 shares in the last quarter. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on STRO. Citizens Jmp raised shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective for the company in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. HC Wainwright increased their price objective on shares of Sutro Biopharma to $10.00 and gave the company a “neutral” rating in a report on Monday, December 22nd. Citigroup upgraded shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Sutro Biopharma currently has an average rating of “Hold” and an average price target of $31.83.

Sutro Biopharma Price Performance

Shares of STRO opened at $20.47 on Monday. The firm’s 50 day moving average is $14.46 and its 200-day moving average is $11.04. Sutro Biopharma, Inc. has a 12-month low of $5.23 and a 12-month high of $20.93. The stock has a market capitalization of $174.20 million, a P/E ratio of -0.78 and a beta of 1.47.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.